Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

A 2'FY-RNA Motif Defines an Aptamer for Ebolavirus Secreted Protein.

Shubham S, Hoinka J, Banerjee S, Swanson E, Dillard JA, Lennemann NJ, Przytycka TM, Maury W, Nilsen-Hamilton M.

Sci Rep. 2018 Aug 17;8(1):12373. doi: 10.1038/s41598-018-30590-8.

2.

Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation.

Iampietro M, Santos RI, Lubaki NM, Bukreyev A.

J Infect Dis. 2018 Nov 22;218(suppl_5):S327-S334. doi: 10.1093/infdis/jiy406.

PMID:
30085081
3.

Ebolaviruses: New roles for old proteins.

Cantoni D, Rossman JS.

PLoS Negl Trop Dis. 2018 May 3;12(5):e0006349. doi: 10.1371/journal.pntd.0006349. eCollection 2018 May. Review.

4.

Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination.

Koch B, Schult-Dietrich P, Büttner S, Dilmaghani B, Lohmann D, Baer PC, Dietrich U, Geiger H.

Blood Purif. 2018;46(2):126-133. doi: 10.1159/000487224. Epub 2018 Apr 26.

5.

Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism.

Seesuay W, Jittavisutthikul S, Sae-Lim N, Sookrung N, Sakolvaree Y, Chaicumpa W.

Emerg Microbes Infect. 2018 Mar 21;7(1):41. doi: 10.1038/s41426-018-0031-3.

6.

Immune barriers of Ebola virus infection.

McElroy AK, Mühlberger E, Muñoz-Fontela C.

Curr Opin Virol. 2018 Feb;28:152-160. doi: 10.1016/j.coviro.2018.01.010. Epub 2018 Feb 16. Review.

PMID:
29452995
7.

A Single Amino Acid Change in the Marburg Virus Glycoprotein Arises during Serial Cell Culture Passages and Attenuates the Virus in a Macaque Model of Disease.

Alfson KJ, Avena LE, Delgado J, Beadles MW, Patterson JL, Carrion R Jr, Griffiths A.

mSphere. 2018 Jan 3;3(1). pii: e00401-17. doi: 10.1128/mSphere.00401-17. eCollection 2018 Jan-Feb.

8.

Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis.

Menicucci AR, Versteeg K, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jankeel A, Geisbert TW, Messaoudi I.

Front Immunol. 2017 Oct 26;8:1372. doi: 10.3389/fimmu.2017.01372. eCollection 2017.

9.

Cooperation of the Ebola Virus Proteins VP40 and GP1,2 with BST2 To Activate NF-κB Independently of Virus-Like Particle Trapping.

Rizk MG, Basler CF, Guatelli J.

J Virol. 2017 Oct 27;91(22). pii: e01308-17. doi: 10.1128/JVI.01308-17. Print 2017 Nov 15.

10.

Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4.

Lai CY, Strange DP, Wong TAS, Lehrer AT, Verma S.

Front Microbiol. 2017 Aug 17;8:1571. doi: 10.3389/fmicb.2017.01571. eCollection 2017.

11.

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.

Versteeg K, Menicucci AR, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jeske D, Messaoudi I, Geisbert TW.

Sci Rep. 2017 Aug 29;7(1):9730. doi: 10.1038/s41598-017-09963-y.

12.

HEMO, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors.

Heidmann O, Béguin A, Paternina J, Berthier R, Deloger M, Bawa O, Heidmann T.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6642-E6651. doi: 10.1073/pnas.1702204114. Epub 2017 Jul 24.

13.

Filovirus Strategies to Escape Antiviral Responses.

Olejnik J, Hume AJ, Leung DW, Amarasinghe GK, Basler CF, Mühlberger E.

Curr Top Microbiol Immunol. 2017;411:293-322. doi: 10.1007/82_2017_13.

14.

Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection.

Iampietro M, Younan P, Nishida A, Dutta M, Lubaki NM, Santos RI, Koup RA, Katze MG, Bukreyev A.

PLoS Pathog. 2017 May 22;13(5):e1006397. doi: 10.1371/journal.ppat.1006397. eCollection 2017 May.

15.

Ebola Virus Delta Peptide is a Viroporin.

He J, Melnik LI, Komin A, Wiedman G, Fuselier T, Morris CF, Starr CG, Searson PC, Gallaher WR, Hristova K, Garry RF, Wimley WC.

J Virol. 2017 May 24. pii: JVI.00438-17. doi: 10.1128/JVI.00438-17. [Epub ahead of print]

16.

THE STRENGTHS, WEAKNESSES, OPPORTUNITIES, AND THREATS (SWOTs) ANALYSES OF THE EBOLA VIRUS - PAPER RETRACTED.

Babalola MO.

Afr J Infect Dis. 2016 May 1;10(2):69-88. doi: 10.21010/ajid.v10i2.2. eCollection 2016.

17.

The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge.

Younan P, Ramanathan P, Graber J, Gusovsky F, Bukreyev A.

MBio. 2017 Apr 25;8(2). pii: e00226-17. doi: 10.1128/mBio.00226-17.

18.

Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection.

Liu Q, Fan C, Li Q, Zhou S, Huang W, Wang L, Sun C, Wang M, Wu X, Ma J, Li B, Xie L, Wang Y.

Sci Rep. 2017 Mar 30;7:45552. doi: 10.1038/srep45552.

19.

Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Olejnik J, Forero A, Deflubé LR, Hume AJ, Manhart WA, Nishida A, Marzi A, Katze MG, Ebihara H, Rasmussen AL, Mühlberger E.

J Virol. 2017 May 12;91(11). pii: e00179-17. doi: 10.1128/JVI.00179-17. Print 2017 Jun 1.

20.

Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.

Pyankov OV, Setoh YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Watterson D, Marsh G, Young PR, Agafonov AA, Farmer JF, Volchkov VE, Suhrbier A, Khromykh AA.

Sci Rep. 2017 Feb 3;7:41537. doi: 10.1038/srep41537.

Supplemental Content

Support Center